Donor and recipient demographic, disease, and transplantation characteristics according to HLA-DPB1 status (matched, permissive, nonpermissive mismatch)
| Variable . | Fully matched . | Permissive . | Nonpermissive . | P value . |
|---|---|---|---|---|
| Number of patients | 763 | 3177 | 1075 | |
| Number of centers | 132 | 167 | 143 | |
| Median (range) | 37 (1-72) | 36 (< 1-74) | 35 (1-70) | .16 |
| Age in decades (years) | .08 | |||
| <10 | 63 (8) | 268 (8) | 108 (10) | |
| 10-19 | 102 (13) | 439 (14) | 137 (13) | |
| 20-29 | 133 (17) | 546 (17) | 176 (16) | |
| 30-39 | 135 (18) | 530 (17) | 213 (20) | |
| 40-49 | 154 (20) | 676 (21) | 245 (23) | |
| 50-59 | 133 (17) | 573 (18) | 158 (15) | |
| >60 | 43 (6) | 145 (5) | 38 (4) | |
| Recipient gender | .98 | |||
| Male | 419 (55) | 1752 (55) | 589 (55) | |
| Female | 344 (45) | 1425 (45) | 486 (45) | |
| Recipient race | .002 | |||
| White | 668 (88) | 2803 (88) | 964 (90) | |
| African American | 24 (3) | 167 (5) | 41 (4) | |
| Other | 62 (8) | 162 (5) | 61 (6) | |
| Missing | 9 (1) | 45 (1) | 9 (<1) | |
| Karnofsky score prior to HCT (%) | .76 | |||
| <90 | 180 (24) | 785 (25) | 256 (24) | |
| 90-100 | 516 (68) | 2094 (66) | 728 (68) | |
| Missing | 67 (9) | 298 (9) | 91 (8) | |
| Disease at HCT | .05 | |||
| AML | 353 (46) | 1499 (47) | 461 (43) | |
| ALL | 218 (29) | 913 (29) | 315 (29) | |
| CML | 128 (17) | 475 (15) | 205 (19) | |
| MDS | 64 (8) | 290 (9) | 94 (9) | |
| Disease status at HCT | .40 | |||
| Early | 313 (41) | 1353 (43) | 455 (42) | |
| Intermediate | 257 (34) | 958 (30) | 323 (30) | |
| Advanced | 193 (25) | 866 (27) | 297 (28) | |
| Graft type | <.001 | |||
| Bone marrow | 406 (53) | 1494 (47) | 651 (61) | |
| Peripheral blood | 357 (47) | 1683 (53) | 424 (39) | |
| Median (range) | 35 (19-60) | 34 (18-61) | 35 (18-60) | .27 |
| Donor age (years) | .34 | |||
| 18-32 | 349 (46) | 1428 (45) | 439 (41) | |
| 33-49 | 351 (46) | 1478 (47) | 540 (50) | |
| ≥50 | 50 (7) | 219 (7) | 75 (7) | |
| Missing | 13 (2) | 52 (2) | 21 (2) | |
| Donor/recipient gender match | .84 | |||
| M/M | 273 (36) | 1164 (37) | 410 (38) | |
| M/F | 204 (27) | 849 (27) | 278 (26) | |
| F/M | 146 (19) | 588 (19) | 179 (17) | |
| F/F | 140 (18) | 575 (18) | 208 (19) | |
| Missing | 0 | 1 (< 1) | 0 | |
| Donor/recipient CMV match | .10 | |||
| −/− | 218 (29) | 973 (31) | 363 (34) | |
| −/+ | 242 (32) | 1078 (34) | 326 (30) | |
| +/− | 112 (15) | 417 (13) | 141 (13) | |
| +/+ | 181 (24) | 666 (21) | 224 (21) | |
| Missing | 10 (1) | 43 (1) | 21 (2) | |
| Donor/recipient ABO match | .009 | |||
| Matched | 316 (41) | 1304 (41) | 407 (38) | |
| Minor mismatch | 183 (24) | 715 (23) | 262 (24) | |
| Major mismatch | 153 (20) | 753 (24) | 250 (23) | |
| Bidirectional mismatch | 48 (6) | 241 (8) | 91 (8) | |
| Unknown | 63 (8) | 164 (5) | 65 (6) | |
| Total body irradiation | <.001 | |||
| No | 266 (35) | 1271 (40) | 347 (32) | |
| Yes | 488 (64) | 1876 (59) | 711 (66) | |
| Missing | 9 (1) | 30 (<1) | 17 (2) | |
| In vivo T-cell depletion (ATG or campath) | .39 | |||
| No | 530 (69) | 2286 (72) | 771 (72) | |
| Yes | 233 (31) | 891 (28) | 304 (28) | |
| HLA matching for -A, -B, -C, and -DRB1 | <.001 | |||
| 8/8 high-resolution matched | 546 (72) | 2083 (66) | 653 (61) | |
| 7/8 single allele MM | 62 (8) | 320 (10) | 121 (11) | |
| 7/8 single antigen MM | 107 (14) | 534 (17) | 183 (17) | |
| 6/8 2 allele MM | 11 (1) | 40 (1) | 13 (1) | |
| 6/8 1 allele and 1 antigen MM | 24 (3) | 118 (4) | 65 (6) | |
| 6/8 2 antigen MM | 13 (2) | 82 (3) | 40 (4) | |
| C*03:03/03:04 mismatch | <.001 | |||
| 7/8 and C*03:03/03:04 mm | 4 (<1) | 42 (1) | 17 (2) | |
| 7/8 and other allele mm at C | 4 (<1) | 27 (<1) | 13 (1) | |
| 7/8 and other antigen mm at C | 55 (7) | 285 (9) | 100 (9) | |
| 7/8 and other non C mismatch | 106 (14) | 500 (16) | 174 (16) | |
| 8/8 | 546 (72) | 2083 (66) | 653 (61) | |
| 6/8 | 48 (6) | 240 (8) | 118 (11) | |
| GVHD prophylaxis | <.001 | |||
| FK506 + (MTX or MMF) + other | 431 (56) | 1741 (55) | 498 (46) | |
| FK506 + other | 45 (6) | 161 (5) | 38 (4) | |
| CsA + MTX + other | 209 (27) | 874 (28) | 377 (35) | |
| CsA + other (no MTX) | 14 (2) | 101 (3) | 26 (2) | |
| T-cell depletion | 47 (6) | 231 (7) | 115 (11) | |
| Other | 17 (2) | 69 (2) | 21 (2) | |
| Year of HSCT | <.001 | |||
| 1999-2002 | 236 (31) | 725 (23) | 542 (50) | |
| 2003-2006 | 257 (34) | 1362 (43) | 288 (27) | |
| 2007-2011 | 270 (35) | 1090 (34) | 245 (23) | |
| Median follow-up of survivors (range), months | 67 (5-149) | 62 (3-150) | 74 (3-151) |
| Variable . | Fully matched . | Permissive . | Nonpermissive . | P value . |
|---|---|---|---|---|
| Number of patients | 763 | 3177 | 1075 | |
| Number of centers | 132 | 167 | 143 | |
| Median (range) | 37 (1-72) | 36 (< 1-74) | 35 (1-70) | .16 |
| Age in decades (years) | .08 | |||
| <10 | 63 (8) | 268 (8) | 108 (10) | |
| 10-19 | 102 (13) | 439 (14) | 137 (13) | |
| 20-29 | 133 (17) | 546 (17) | 176 (16) | |
| 30-39 | 135 (18) | 530 (17) | 213 (20) | |
| 40-49 | 154 (20) | 676 (21) | 245 (23) | |
| 50-59 | 133 (17) | 573 (18) | 158 (15) | |
| >60 | 43 (6) | 145 (5) | 38 (4) | |
| Recipient gender | .98 | |||
| Male | 419 (55) | 1752 (55) | 589 (55) | |
| Female | 344 (45) | 1425 (45) | 486 (45) | |
| Recipient race | .002 | |||
| White | 668 (88) | 2803 (88) | 964 (90) | |
| African American | 24 (3) | 167 (5) | 41 (4) | |
| Other | 62 (8) | 162 (5) | 61 (6) | |
| Missing | 9 (1) | 45 (1) | 9 (<1) | |
| Karnofsky score prior to HCT (%) | .76 | |||
| <90 | 180 (24) | 785 (25) | 256 (24) | |
| 90-100 | 516 (68) | 2094 (66) | 728 (68) | |
| Missing | 67 (9) | 298 (9) | 91 (8) | |
| Disease at HCT | .05 | |||
| AML | 353 (46) | 1499 (47) | 461 (43) | |
| ALL | 218 (29) | 913 (29) | 315 (29) | |
| CML | 128 (17) | 475 (15) | 205 (19) | |
| MDS | 64 (8) | 290 (9) | 94 (9) | |
| Disease status at HCT | .40 | |||
| Early | 313 (41) | 1353 (43) | 455 (42) | |
| Intermediate | 257 (34) | 958 (30) | 323 (30) | |
| Advanced | 193 (25) | 866 (27) | 297 (28) | |
| Graft type | <.001 | |||
| Bone marrow | 406 (53) | 1494 (47) | 651 (61) | |
| Peripheral blood | 357 (47) | 1683 (53) | 424 (39) | |
| Median (range) | 35 (19-60) | 34 (18-61) | 35 (18-60) | .27 |
| Donor age (years) | .34 | |||
| 18-32 | 349 (46) | 1428 (45) | 439 (41) | |
| 33-49 | 351 (46) | 1478 (47) | 540 (50) | |
| ≥50 | 50 (7) | 219 (7) | 75 (7) | |
| Missing | 13 (2) | 52 (2) | 21 (2) | |
| Donor/recipient gender match | .84 | |||
| M/M | 273 (36) | 1164 (37) | 410 (38) | |
| M/F | 204 (27) | 849 (27) | 278 (26) | |
| F/M | 146 (19) | 588 (19) | 179 (17) | |
| F/F | 140 (18) | 575 (18) | 208 (19) | |
| Missing | 0 | 1 (< 1) | 0 | |
| Donor/recipient CMV match | .10 | |||
| −/− | 218 (29) | 973 (31) | 363 (34) | |
| −/+ | 242 (32) | 1078 (34) | 326 (30) | |
| +/− | 112 (15) | 417 (13) | 141 (13) | |
| +/+ | 181 (24) | 666 (21) | 224 (21) | |
| Missing | 10 (1) | 43 (1) | 21 (2) | |
| Donor/recipient ABO match | .009 | |||
| Matched | 316 (41) | 1304 (41) | 407 (38) | |
| Minor mismatch | 183 (24) | 715 (23) | 262 (24) | |
| Major mismatch | 153 (20) | 753 (24) | 250 (23) | |
| Bidirectional mismatch | 48 (6) | 241 (8) | 91 (8) | |
| Unknown | 63 (8) | 164 (5) | 65 (6) | |
| Total body irradiation | <.001 | |||
| No | 266 (35) | 1271 (40) | 347 (32) | |
| Yes | 488 (64) | 1876 (59) | 711 (66) | |
| Missing | 9 (1) | 30 (<1) | 17 (2) | |
| In vivo T-cell depletion (ATG or campath) | .39 | |||
| No | 530 (69) | 2286 (72) | 771 (72) | |
| Yes | 233 (31) | 891 (28) | 304 (28) | |
| HLA matching for -A, -B, -C, and -DRB1 | <.001 | |||
| 8/8 high-resolution matched | 546 (72) | 2083 (66) | 653 (61) | |
| 7/8 single allele MM | 62 (8) | 320 (10) | 121 (11) | |
| 7/8 single antigen MM | 107 (14) | 534 (17) | 183 (17) | |
| 6/8 2 allele MM | 11 (1) | 40 (1) | 13 (1) | |
| 6/8 1 allele and 1 antigen MM | 24 (3) | 118 (4) | 65 (6) | |
| 6/8 2 antigen MM | 13 (2) | 82 (3) | 40 (4) | |
| C*03:03/03:04 mismatch | <.001 | |||
| 7/8 and C*03:03/03:04 mm | 4 (<1) | 42 (1) | 17 (2) | |
| 7/8 and other allele mm at C | 4 (<1) | 27 (<1) | 13 (1) | |
| 7/8 and other antigen mm at C | 55 (7) | 285 (9) | 100 (9) | |
| 7/8 and other non C mismatch | 106 (14) | 500 (16) | 174 (16) | |
| 8/8 | 546 (72) | 2083 (66) | 653 (61) | |
| 6/8 | 48 (6) | 240 (8) | 118 (11) | |
| GVHD prophylaxis | <.001 | |||
| FK506 + (MTX or MMF) + other | 431 (56) | 1741 (55) | 498 (46) | |
| FK506 + other | 45 (6) | 161 (5) | 38 (4) | |
| CsA + MTX + other | 209 (27) | 874 (28) | 377 (35) | |
| CsA + other (no MTX) | 14 (2) | 101 (3) | 26 (2) | |
| T-cell depletion | 47 (6) | 231 (7) | 115 (11) | |
| Other | 17 (2) | 69 (2) | 21 (2) | |
| Year of HSCT | <.001 | |||
| 1999-2002 | 236 (31) | 725 (23) | 542 (50) | |
| 2003-2006 | 257 (34) | 1362 (43) | 288 (27) | |
| 2007-2011 | 270 (35) | 1090 (34) | 245 (23) | |
| Median follow-up of survivors (range), months | 67 (5-149) | 62 (3-150) | 74 (3-151) |